340 related articles for article (PubMed ID: 31234232)
1. SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.
Fernández-Santiago R; Martín-Flores N; Antonelli F; Cerquera C; Moreno V; Bandres-Ciga S; Manduchi E; Tolosa E; Singleton AB; Moore JH; ; Martí MJ; Ezquerra M; Malagelada C
Mov Disord; 2019 Sep; 34(9):1333-1344. PubMed ID: 31234232
[TBL] [Abstract][Full Text] [Related]
2. MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.
Martín-Flores N; Fernández-Santiago R; Antonelli F; Cerquera C; Moreno V; Martí MJ; Ezquerra M; Malagelada C
Mol Neurobiol; 2019 Mar; 56(3):2092-2100. PubMed ID: 29992529
[TBL] [Abstract][Full Text] [Related]
3. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
[TBL] [Abstract][Full Text] [Related]
4. Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?
Biernacka JM; Armasu SM; Cunningham JM; Ahlskog JE; Chung SJ; Maraganore DM
Parkinsonism Relat Disord; 2011 Dec; 17(10):730-6. PubMed ID: 21816655
[TBL] [Abstract][Full Text] [Related]
5. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M;
Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656
[TBL] [Abstract][Full Text] [Related]
6. Age at onset in LRRK2-associated PD is modified by SNCA variants.
Botta-Orfila T; Ezquerra M; Pastor P; Fernández-Santiago R; Pont-Sunyer C; Compta Y; Lorenzo-Betancor O; Samaranch L; Martí MJ; Valldeoriola F; Calopa M; Fernández M; Aguilar M; de Fabregas O; Hernández-Vara J; Tolosa E
J Mol Neurosci; 2012 Sep; 48(1):245-7. PubMed ID: 22669510
[TBL] [Abstract][Full Text] [Related]
7. SNCA variants and alpha-synuclein level in CD45+ blood cells in Parkinson's disease.
Emelyanov A; Kulabukhova D; Garaeva L; Senkevich K; Verbitskaya E; Nikolaev M; Andoskin P; Kopytova A; Milyukhina I; Yakimovskii A; Timofeeva A; Prakhova L; Ilves A; Vlasova I; Pchelina S
J Neurol Sci; 2018 Dec; 395():135-140. PubMed ID: 30316070
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: a replication study in a Taiwanese cohort.
Wu-Chou YH; Chen YT; Yeh TH; Chang HC; Weng YH; Lai SC; Huang CL; Chen RS; Huang YZ; Chen CC; Hung J; Chuang WL; Lin WY; Chen CH; Lu CS
Parkinsonism Relat Disord; 2013 Feb; 19(2):251-5. PubMed ID: 23182315
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein gene polymorphism affects risk of dementia in Han Chinese with Parkinson's disease.
Zheng J; Zang Q; Hu F; Wei H; Ma J; Xu Y
Neurosci Lett; 2019 Jul; 706():146-150. PubMed ID: 31102707
[TBL] [Abstract][Full Text] [Related]
10. [SNCA rs356219 AND rs356165 VARIANTS ARE ASSOCIATED WITH PARKINSON'S DISEASE AND INCREASED ALPHA-SYNUCLEIN GENE EXPRESSION IN THE CD45(+)-BLOOD CELLS].
Emelyanov AK; Andoskin PA; Miliukhina IV; Timofeeva AA; Yakimovskii AF; Senkevich KA; Nikolaev MA; Pchelina SN
Tsitologiia; 2016; 58(2):99-104. PubMed ID: 27228655
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein (SNCA) polymorphisms and susceptibility to Parkinson's disease: a meta-analysis.
Han W; Liu Y; Mi Y; Zhao J; Liu D; Tian Q
Am J Med Genet B Neuropsychiatr Genet; 2015 Mar; 168B(2):123-34. PubMed ID: 25656566
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms.
Blauwendraat C; Heilbron K; Vallerga CL; Bandres-Ciga S; von Coelln R; Pihlstrøm L; Simón-Sánchez J; Schulte C; Sharma M; Krohn L; Siitonen A; Iwaki H; Leonard H; Noyce AJ; Tan M; Gibbs JR; Hernandez DG; Scholz SW; Jankovic J; Shulman LM; Lesage S; Corvol JC; Brice A; van Hilten JJ; Marinus J; ; Eerola-Rautio J; Tienari P; Majamaa K; Toft M; Grosset DG; Gasser T; Heutink P; Shulman JM; Wood N; Hardy J; Morris HR; Hinds DA; Gratten J; Visscher PM; Gan-Or Z; Nalls MA; Singleton AB;
Mov Disord; 2019 Jun; 34(6):866-875. PubMed ID: 30957308
[TBL] [Abstract][Full Text] [Related]
13. α-syn and SNP rs356219 as a potential biomarker in blood for Parkinson's disease in Mexican Mestizos.
Salas-Leal AC; Salas-Pacheco SM; Gavilán-Ceniceros JAP; Castellanos-Juárez FX; Méndez-Hernández EM; La Llave-León O; Camacho-Luis A; Quiñones-Canales G; Romero-Gutiérrez E; Arias-Carrión O; Salas-Pacheco JM; Sandoval-Carrillo AA
Neurosci Lett; 2021 May; 754():135901. PubMed ID: 33865938
[TBL] [Abstract][Full Text] [Related]
14. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.
Mata IF; Shi M; Agarwal P; Chung KA; Edwards KL; Factor SA; Galasko DR; Ginghina C; Griffith A; Higgins DS; Kay DM; Kim H; Leverenz JB; Quinn JF; Roberts JW; Samii A; Snapinn KW; Tsuang DW; Yearout D; Zhang J; Payami H; Zabetian CP
Arch Neurol; 2010 Nov; 67(11):1350-6. PubMed ID: 21060011
[TBL] [Abstract][Full Text] [Related]
15. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease.
Elbaz A; Ross OA; Ioannidis JP; Soto-Ortolaza AI; Moisan F; Aasly J; Annesi G; Bozi M; Brighina L; Chartier-Harlin MC; Destée A; Ferrarese C; Ferraris A; Gibson JM; Gispert S; Hadjigeorgiou GM; Jasinska-Myga B; Klein C; Krüger R; Lambert JC; Lohmann K; van de Loo S; Loriot MA; Lynch T; Mellick GD; Mutez E; Nilsson C; Opala G; Puschmann A; Quattrone A; Sharma M; Silburn PA; Stefanis L; Uitti RJ; Valente EM; Vilariño-Güell C; Wirdefeldt K; Wszolek ZK; Xiromerisiou G; Maraganore DM; Farrer MJ;
Ann Neurol; 2011 May; 69(5):778-92. PubMed ID: 21391235
[TBL] [Abstract][Full Text] [Related]
16. SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study.
Wider C; Vilariño-Güell C; Heckman MG; Jasinska-Myga B; Ortolaza-Soto AI; Diehl NN; Crook JE; Cobb SA; Bacon JA; Aasly JO; Gibson JM; Lynch T; Uitti RJ; Wszolek ZK; Farrer MJ; Ross OA
Eur J Neurol; 2011 Jun; 18(6):876-81. PubMed ID: 21159074
[TBL] [Abstract][Full Text] [Related]
17. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease.
Mata IF; Yearout D; Alvarez V; Coto E; de Mena L; Ribacoba R; Lorenzo-Betancor O; Samaranch L; Pastor P; Cervantes S; Infante J; Garcia-Gorostiaga I; Sierra M; Combarros O; Snapinn KW; Edwards KL; Zabetian CP
Mov Disord; 2011 Apr; 26(5):819-23. PubMed ID: 21425343
[TBL] [Abstract][Full Text] [Related]
18. SNCA: major genetic modifier of age at onset of Parkinson's disease.
Brockmann K; Schulte C; Hauser AK; Lichtner P; Huber H; Maetzler W; Berg D; Gasser T
Mov Disord; 2013 Aug; 28(9):1217-21. PubMed ID: 23674386
[TBL] [Abstract][Full Text] [Related]
19. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients.
Boros FA; Török R; Vágvölgyi-Sümegi E; Pesei ZG; Klivényi P; Vécsei L
Neurosci Lett; 2019 Jul; 706():140-145. PubMed ID: 31085292
[TBL] [Abstract][Full Text] [Related]
20. SNCA rs356182 variant increases risk of sporadic Parkinson's disease in ethnic Chinese.
Cheng L; Wang L; Li NN; Yu WJ; Sun XY; Li JY; Zhou D; Peng R
J Neurol Sci; 2016 Sep; 368():231-4. PubMed ID: 27538639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
